Entry - #266510 - PEROXISOME BIOGENESIS DISORDER 3B; PBD3B - OMIM
# 266510

PEROXISOME BIOGENESIS DISORDER 3B; PBD3B


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
17q12 Peroxisome biogenesis disorder 3B 266510 AR 3 PEX12 601758
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
GROWTH
Other
- Failure to thrive
HEAD & NECK
Face
- Minor facial dysmorphism
- Flat face
Ears
- Sensorineural deafness
Eyes
- Abnormal ERG
- Retinitis pigmentosa
- Retinal dystrophy
Nose
- Flat nose
ABDOMEN
Liver
- Hepatomegaly
Gastrointestinal
- Steatorrhea
SKELETAL
- Osteoporosis
SKIN, NAILS, & HAIR
Skin
- Simian crease
NEUROLOGIC
Central Nervous System
- Mental retardation
- Hypotonia
- Developmental delay
Peripheral Nervous System
- Decreased deep tendon reflexes
- Peripheral neuropathy
HEMATOLOGY
- Episodic bleeding
LABORATORY ABNORMALITIES
- Hypocholesterolemia
- Phytanic acid accumulation
- Very long chain fatty acid accumulation
- Di- and trihydroxycholestanoic acid accumulation
- Pipecolic acid accumulation.
- Peroxisome deficiency
- Defective bile acid metabolism
MISCELLANEOUS
- Prenatal onset
MOLECULAR BASIS
- Caused by mutation in the peroxisome biogenesis factor-2 gene (PEX2, 170993.0002)
Peroxisome biogenesis disorder - PS214100 - 27 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.32 Peroxisome biogenesis disorder 6B AR 3 614871 PEX10 602859
1p36.32 Peroxisome biogenesis disorder 6A (Zellweger) AR 3 614870 PEX10 602859
1p36.22 Peroxisome biogenesis disorder 13A (Zellweger) AR 3 614887 PEX14 601791
1q21.1 Peroxisome biogenesis disorder 14B AR 3 614920 PEX11B 603867
1q23.2 Peroxisome biogenesis disorder 12A (Zellweger) AR 3 614886 PEX19 600279
2p15 Peroxisome biogenesis disorder 11A (Zellweger) AR 3 614883 PEX13 601789
2p15 Peroxisome biogenesis disorder 11B AR 3 614885 PEX13 601789
6p21.1 Peroxisome biogenesis disorder 4B AD, AR 3 614863 PEX6 601498
6p21.1 Peroxisome biogenesis disorder 4A (Zellweger) AR 3 614862 PEX6 601498
6p21.1 Heimler syndrome 2 AR 3 616617 PEX6 601498
6q23.3 Rhizomelic chondrodysplasia punctata, type 1 AR 3 215100 PEX7 601757
6q23.3 Peroxisome biogenesis disorder 9B AR 3 614879 PEX7 601757
6q24.2 Peroxisome biogenesis disorder 10A (Zellweger) AR 3 614882 PEX3 603164
6q24.2 ?Peroxisome biogenesis disorder 10B AR 3 617370 PEX3 603164
7q21.2 Peroxisome biogenesis disorder 1B (NALD/IRD) AR 3 601539 PEX1 602136
7q21.2 Peroxisome biogenesis disorder 1A (Zellweger) AR 3 214100 PEX1 602136
7q21.2 Heimler syndrome 1 AR 3 234580 PEX1 602136
8q21.13 Peroxisome biogenesis disorder 5A (Zellweger) AR 3 614866 PEX2 170993
8q21.13 Peroxisome biogenesis disorder 5B AR 3 614867 PEX2 170993
11p11.2 Peroxisome biogenesis disorder 8B AR 3 614877 PEX16 603360
11p11.2 Peroxisome biogenesis disorder 8A (Zellweger) AR 3 614876 PEX16 603360
12p13.31 Peroxisome biogenesis disorder 2A (Zellweger) AR 3 214110 PEX5 600414
12p13.31 Peroxisome biogenesis disorder 2B AR 3 202370 PEX5 600414
17q12 Peroxisome biogenesis disorder 3B AR 3 266510 PEX12 601758
17q12 Peroxisome biogenesis disorder 3A (Zellweger) AR 3 614859 PEX12 601758
22q11.21 Peroxisome biogenesis disorder 7B AR 3 614873 PEX26 608666
22q11.21 Peroxisome biogenesis disorder 7A (Zellweger) AR 3 614872 PEX26 608666

TEXT

A number sign (#) is used with this entry because this form of peroxisome biogenesis disorder (PBD3B) is caused by homozygous or compound heterozygous mutation in the PEX12 gene (601758) on chromosome 17. Mutations in the PEX12 gene also cause Zellweger syndrome (PBD3A; 614859).


Description

The overlapping phenotypes of neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) represent the milder manifestations of the Zellweger syndrome spectrum (ZSS) of peroxisome biogenesis disorders. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy, and visual impairment. Children with the NALD presentation may reach their teens, and those with the IRD presentation may reach adulthood (summary by Waterham and Ebberink, 2012).

For a complete phenotypic description and a discussion of genetic heterogeneity of PBD(NALD/IRD), see 601539.

Individuals with mutations in the PEX12 gene have cells of complementation group 3 (CG3). For information on the history of PBD complementation groups, see 214100.


Clinical Features

Christensen et al. (1990) described a patient with ataxia, dysarthric speech, dry skin, hypotonia, and absent reflexes.

Gootjes et al. (2004) reinvestigated the patient of Christensen et al. (1990), a girl from unrelated parents. At age 5 years, an elevated plasma level of phytanic acid was found, and physical examination revealed psychomotor retardation, hypotonia, ataxia, dysarthria, convergent strabismus, nystagmus, and absent deep tendon reflexes. CT of the brain, EMG, nerve conduction velocity (NCV), visual evoked potential (VEP), electroretinogram (ERG), auditory brainstem response (ABR), and somatosensory evoked potential (SSEP) were within normal limits. She was unable to walk without support. After treatment with a phytanic acid-restricted diet, she was able to take 3 or 4 steps without support. Bilateral sensory hearing loss was detected at age 8 years. Mental evaluation at age 15 years revealed a functional level of 7 to 8 years. Bilateral Achilles tendon extensions were performed at age 16 years. Because of persistent ataxia and instability of the lower extremities, triple arthrodeses of the ankles was done at age 20 and 22 years. She was eventually able to take approximately 30 steps without support. Electroretinogram at age 18 years showed lack of flicker response at 32 Hz, and ophthalmoscopy suggested early retinitis pigmentosa. She had no dysmorphic features.

Gootjes et al. (2004) described a patient, the child of consanguineous Arab Muslim parents, with a comparatively mild peroxisomal biogenesis disorder who was alive at the age of 8 years. The patient had broad nasal bridge, hypertelorism, external ear deformity, hypotonia, and psychomotor retardation. No cataract was present but there was nystagmus and hearing deficit. By age 4 years the patient could not sit or walk unsupported and had no intentional hand use.


Biochemical Features

Christensen et al. (1990) found that their patient had elevated plasma levels of phytanic acid and bile acid intermediates, but normal phytanic acid oxidation in fibroblasts. Furthermore, C26:0 beta-oxidation, very long chain fatty acids (VLCFA) levels, dihydroxyacetonephosphate-acyltransferase (DHAPAT) activity, and de novo plasmalogen biosynthesis in fibroblasts were normal.

Ten Brink et al. (1994) found that pristanic acid was also elevated in plasma from this patient. Phytanic acid levels in plasma normalized after the patient was prescribed a phytanic acid-restricted diet, whereas pristanic acid remained elevated. It was concluded that the patient had a deficiency of the enzyme responsible for the first step of beta-oxidation of DHCA, THCA, and pristanic acid.


Clinical Management

Gootjes et al. (2004) reported that a phytanic acid-restricted diet in their patient caused plasma phytanic acid to decrease to trace levels, where they remained. The diet improved motor strength and balance, and she was able to take 3 or 4 steps without support.


Molecular Genetics

In a patient with a mild peroxisomal biogenesis disorder of complementation group 3 who had originally been diagnosed with trihydroxycholestanoyl-CoA oxidase deficiency, Gootjes et al. (2004) detected compound heterozygosity for a nonsense mutation (R180X; 601758.0005) and a missense mutation (L317F; 601758.0010) in the PEX12 gene.

Gootjes et al. (2004) studied 8 patients with peroxisomal biogenesis disorder (PBD) of relatively mild types compared to the entire PBD spectrum. Seven of these patients came from consanguineous families; in the eighth patient this was unknown. All patients had been diagnosed with neonatal adrenoleukodystrophy or infantile Refsum disease, or had overlapping symptoms. In all of these patients a homozygous missense mutation (S320F; 601758.0006) in the PEX12 gene was found.


REFERENCES

  1. Christensen, E., Van Eldere, J., Brandt, N. J., Schutgens, R. B. H., Wanders, R. J. A., Eyssen, H. J. A new peroxisomal disorder: di- and trihydroxycholestanaemia due to a presumed trihydroxycholestanoyl-CoA oxidase deficiency. J. Inherit. Metab. Dis. 13: 363-366, 1990. [PubMed: 2122101, related citations] [Full Text]

  2. Gootjes, J., Schmohl, F., Waterham, H. R., Wanders, R. J. A. Novel mutations in the PEX12 gene of patients with a peroxisome biogenesis disorder. Europ. J. Hum. Genet. 12: 115-120, 2004. [PubMed: 14571262, related citations] [Full Text]

  3. Gootjes, J., Skovby, F., Christensen, E., Wanders, R. J. A., Ferdinandusse, S. Reinvestigation of trihydroxycholestanoic acidemia reveals a peroxisome biogenesis disorder. Neurology 62: 2077-2081, 2004. [PubMed: 15184617, related citations] [Full Text]

  4. ten Brink, H. J., Wanders, R. J., Christensen, E., Brandt, N. J., Jakobs, C. Heterogeneity in di/trihydroxycholestanoic acidaemia. Ann. Clin. Biochem. 31: 195-197, 1994. [PubMed: 8060102, related citations] [Full Text]

  5. Waterham, H. R., Ebberink, M. S. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim. Biophys. Acta 1822: 1430-1441, 2012. [PubMed: 22871920, related citations] [Full Text]


Anne M. Stumpf - reorganized : 10/11/2012
Victor A. McKusick - updated : 4/7/2004
Sonja A. Rasmussen - updated : 3/2/2000
Michael J. Wright - updated : 2/4/2000
Victor A. McKusick - updated : 12/1/1997
Creation Date:
Victor A. McKusick : 10/16/1986
alopez : 07/15/2015
alopez : 10/26/2012
alopez : 10/19/2012
alopez : 10/11/2012
terry : 10/10/2011
terry : 10/6/2011
terry : 8/26/2008
ckniffin : 6/16/2004
tkritzer : 4/12/2004
terry : 4/7/2004
carol : 3/4/2003
mcapotos : 3/3/2000
mcapotos : 3/2/2000
alopez : 2/4/2000
carol : 7/27/1999
mark : 12/1/1997
mark : 12/1/1997
terry : 11/26/1997
carol : 2/7/1995
mimadm : 3/12/1994
supermim : 3/17/1992
carol : 5/14/1991
carol : 5/13/1991
supermim : 3/20/1990

# 266510

PEROXISOME BIOGENESIS DISORDER 3B; PBD3B


ORPHA: 44, 772, 79189;   DO: 0081241;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
17q12 Peroxisome biogenesis disorder 3B 266510 Autosomal recessive 3 PEX12 601758

TEXT

A number sign (#) is used with this entry because this form of peroxisome biogenesis disorder (PBD3B) is caused by homozygous or compound heterozygous mutation in the PEX12 gene (601758) on chromosome 17. Mutations in the PEX12 gene also cause Zellweger syndrome (PBD3A; 614859).


Description

The overlapping phenotypes of neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) represent the milder manifestations of the Zellweger syndrome spectrum (ZSS) of peroxisome biogenesis disorders. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy, and visual impairment. Children with the NALD presentation may reach their teens, and those with the IRD presentation may reach adulthood (summary by Waterham and Ebberink, 2012).

For a complete phenotypic description and a discussion of genetic heterogeneity of PBD(NALD/IRD), see 601539.

Individuals with mutations in the PEX12 gene have cells of complementation group 3 (CG3). For information on the history of PBD complementation groups, see 214100.


Clinical Features

Christensen et al. (1990) described a patient with ataxia, dysarthric speech, dry skin, hypotonia, and absent reflexes.

Gootjes et al. (2004) reinvestigated the patient of Christensen et al. (1990), a girl from unrelated parents. At age 5 years, an elevated plasma level of phytanic acid was found, and physical examination revealed psychomotor retardation, hypotonia, ataxia, dysarthria, convergent strabismus, nystagmus, and absent deep tendon reflexes. CT of the brain, EMG, nerve conduction velocity (NCV), visual evoked potential (VEP), electroretinogram (ERG), auditory brainstem response (ABR), and somatosensory evoked potential (SSEP) were within normal limits. She was unable to walk without support. After treatment with a phytanic acid-restricted diet, she was able to take 3 or 4 steps without support. Bilateral sensory hearing loss was detected at age 8 years. Mental evaluation at age 15 years revealed a functional level of 7 to 8 years. Bilateral Achilles tendon extensions were performed at age 16 years. Because of persistent ataxia and instability of the lower extremities, triple arthrodeses of the ankles was done at age 20 and 22 years. She was eventually able to take approximately 30 steps without support. Electroretinogram at age 18 years showed lack of flicker response at 32 Hz, and ophthalmoscopy suggested early retinitis pigmentosa. She had no dysmorphic features.

Gootjes et al. (2004) described a patient, the child of consanguineous Arab Muslim parents, with a comparatively mild peroxisomal biogenesis disorder who was alive at the age of 8 years. The patient had broad nasal bridge, hypertelorism, external ear deformity, hypotonia, and psychomotor retardation. No cataract was present but there was nystagmus and hearing deficit. By age 4 years the patient could not sit or walk unsupported and had no intentional hand use.


Biochemical Features

Christensen et al. (1990) found that their patient had elevated plasma levels of phytanic acid and bile acid intermediates, but normal phytanic acid oxidation in fibroblasts. Furthermore, C26:0 beta-oxidation, very long chain fatty acids (VLCFA) levels, dihydroxyacetonephosphate-acyltransferase (DHAPAT) activity, and de novo plasmalogen biosynthesis in fibroblasts were normal.

Ten Brink et al. (1994) found that pristanic acid was also elevated in plasma from this patient. Phytanic acid levels in plasma normalized after the patient was prescribed a phytanic acid-restricted diet, whereas pristanic acid remained elevated. It was concluded that the patient had a deficiency of the enzyme responsible for the first step of beta-oxidation of DHCA, THCA, and pristanic acid.


Clinical Management

Gootjes et al. (2004) reported that a phytanic acid-restricted diet in their patient caused plasma phytanic acid to decrease to trace levels, where they remained. The diet improved motor strength and balance, and she was able to take 3 or 4 steps without support.


Molecular Genetics

In a patient with a mild peroxisomal biogenesis disorder of complementation group 3 who had originally been diagnosed with trihydroxycholestanoyl-CoA oxidase deficiency, Gootjes et al. (2004) detected compound heterozygosity for a nonsense mutation (R180X; 601758.0005) and a missense mutation (L317F; 601758.0010) in the PEX12 gene.

Gootjes et al. (2004) studied 8 patients with peroxisomal biogenesis disorder (PBD) of relatively mild types compared to the entire PBD spectrum. Seven of these patients came from consanguineous families; in the eighth patient this was unknown. All patients had been diagnosed with neonatal adrenoleukodystrophy or infantile Refsum disease, or had overlapping symptoms. In all of these patients a homozygous missense mutation (S320F; 601758.0006) in the PEX12 gene was found.


REFERENCES

  1. Christensen, E., Van Eldere, J., Brandt, N. J., Schutgens, R. B. H., Wanders, R. J. A., Eyssen, H. J. A new peroxisomal disorder: di- and trihydroxycholestanaemia due to a presumed trihydroxycholestanoyl-CoA oxidase deficiency. J. Inherit. Metab. Dis. 13: 363-366, 1990. [PubMed: 2122101] [Full Text: https://doi.org/10.1007/BF01799396]

  2. Gootjes, J., Schmohl, F., Waterham, H. R., Wanders, R. J. A. Novel mutations in the PEX12 gene of patients with a peroxisome biogenesis disorder. Europ. J. Hum. Genet. 12: 115-120, 2004. [PubMed: 14571262] [Full Text: https://doi.org/10.1038/sj.ejhg.5201090]

  3. Gootjes, J., Skovby, F., Christensen, E., Wanders, R. J. A., Ferdinandusse, S. Reinvestigation of trihydroxycholestanoic acidemia reveals a peroxisome biogenesis disorder. Neurology 62: 2077-2081, 2004. [PubMed: 15184617] [Full Text: https://doi.org/10.1212/01.wnl.0000127576.26352.d1]

  4. ten Brink, H. J., Wanders, R. J., Christensen, E., Brandt, N. J., Jakobs, C. Heterogeneity in di/trihydroxycholestanoic acidaemia. Ann. Clin. Biochem. 31: 195-197, 1994. [PubMed: 8060102] [Full Text: https://doi.org/10.1177/000456329403100217]

  5. Waterham, H. R., Ebberink, M. S. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim. Biophys. Acta 1822: 1430-1441, 2012. [PubMed: 22871920] [Full Text: https://doi.org/10.1016/j.bbadis.2012.04.006]


Contributors:
Anne M. Stumpf - reorganized : 10/11/2012
Victor A. McKusick - updated : 4/7/2004
Sonja A. Rasmussen - updated : 3/2/2000
Michael J. Wright - updated : 2/4/2000
Victor A. McKusick - updated : 12/1/1997

Creation Date:
Victor A. McKusick : 10/16/1986

Edit History:
alopez : 07/15/2015
alopez : 10/26/2012
alopez : 10/19/2012
alopez : 10/11/2012
terry : 10/10/2011
terry : 10/6/2011
terry : 8/26/2008
ckniffin : 6/16/2004
tkritzer : 4/12/2004
terry : 4/7/2004
carol : 3/4/2003
mcapotos : 3/3/2000
mcapotos : 3/2/2000
alopez : 2/4/2000
carol : 7/27/1999
mark : 12/1/1997
mark : 12/1/1997
terry : 11/26/1997
carol : 2/7/1995
mimadm : 3/12/1994
supermim : 3/17/1992
carol : 5/14/1991
carol : 5/13/1991
supermim : 3/20/1990